C. Light Technologies

What C. Light Technologies does

C. Light Technologies is a Berkeley, California-based healthtech company that develops Retitrack™, the first FDA-approved retinal eye movement monitor. The device uses video-based eye tracking combined with AI and machine learning analytics to non-invasively detect and quantify fixational eye movements that are invisible during standard bedside clinical examinations, giving clinicians objective metrics to validate patient experiences and monitor neurological function. The company was founded in 2014 and operates as a private, venture-backed entity with a team of 1-10 employees.

Retitrack™'s primary clinical application is neurodegenerative disease monitoring, with a current focus on Multiple Sclerosis progression biomarkers. Through a selection into the Roche MS Innovation Challenge announced in November 2025, C. Light is collaborating with Roche, UCSF, and Sutter Health on a two-year clinical trial to validate eye movement analysis as an MS disease progression biomarker. A secondary application is elite athletic performance vision assessment, expanding the addressable use cases beyond clinical neurology into sports vision.

The company sells through a direct enterprise sales model targeting healthcare clinics and medical professionals, with three publicly disclosed pricing tiers: a one-time $65,000 full device purchase, a $25,000 upfront fee plus recurring scan fees under a 3-year commitment, and a $15,000 upfront fee plus scan fees under a 5-year commitment. Per-use scan fees create recurring usage-based revenue tied to device utilization. Marketing is conducted through the company website, an ROI calculator, demo booking, and leadership LinkedIn thought leadership. Leadership is anchored by co-founder and CEO Dr. Christy Sheehy-Bensinger (the Retitrack™ inventor and vision science researcher), co-founder and CTO Dr. Joe Xing (ML/AI and optical systems), and CMO Dr. Jacqueline Theis (neuro-optometry and concussion/brain injury specialist).

Name

C. Light Technologies

Legal name

C. Light Technologies

Website

https://clighttechnologies.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

C. Light Technologies develops Retitrack™, the first FDA-approved retinal eye movement monitor that uses AI-driven eye-tracking to detect fixational eye movements invisible at bedside exams, serving healthcare providers for neurodegenerative disease monitoring and clinical diagnostics.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

akta.pro secondary industry

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)

Keywords

• Retinal eye tracking
• Neurodegenerative disease monitoring
• Medical imaging devices
• Clinical eye-tracking systems
• Oculomotor biomarker analysis

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Device Sales - Full Purchase: One-time purchase of Retitrack™ device at $65,000 for full ownership. Clinicians own the device outright and pay per-use scan fees.
2. Device Sales - 3-Year Commitment: Device purchase at $25,000 upfront plus per-use scan fees under a 3-year commitment agreement, providing a lower initial cost barrier while maintaining recurring revenue through scan fees.
3. Device Sales - 5-Year Commitment: Device purchase at $15,000 upfront plus per-use scan fees under a 5-year commitment, offering the lowest entry price with long-term scan fee revenue.
4. Per-Use Scan Fees: Recurring usage-based revenue from scan fees charged per patient test performed on the Retitrack™ device, creating ongoing revenue tied to device utilization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

C. Light Technologies develops and sells the Retitrack™, the first FDA-approved retinal eye movement monitor that non-invasively detects and tracks fixational eye movements invisible at bedside exams. The device is sold to healthcare clinics and clinicians for objective oculomotor assessment and biomarker-driven monitoring of neurodegenerative diseases such as Multiple Sclerosis, with revenue generated through hardware purchases and recurring per-use scan fees.

Product overview

C. Light Technologies offers a single unified product, the Retitrack™ — the first FDA-approved retinal eye movement monitor. This AI-driven eye-tracking device non-invasively detects and tracks fixational eye movements for clinical use, providing clinicians with objective metrics to validate patient experiences. The system is designed for proactive patient outcomes in neurodegenerative disease monitoring and elite athletic performance assessment.

Differentiator

Problem solved

Functional benefit

Brands

• Retitrack™: First FDA-approved retinal eye movement monitor for detecting and tracking fixational eye movements for clinical use.

Products and services

• Retitrack™ The first FDA-approved retinal eye movement monitor that non-invasively detects and tracks fixational eye movements invisible at bedside exams. Used by clinicians to provide objective metrics for validating patient experiences and by researchers studying neurodegenerative disease progression (notably Multiple Sclerosis) and elite athletic performance.

Quantifiable outcome

• Non-invasive detection of fixational eye movements invisible at bedside exams

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• RocheflagshipStrategic or Co-development Partner · 19 November 2025C. Light Technologies was selected as one of five projects in the Roche MS Innovation Challenge. Roche is funding a two-year clinical trial using C. Light's proprietary Retitrack™ technology at UCSF and Sutter Health. The research focuses on using eye movement analysis as a biomarker for Multiple Sclerosis progression, aiming to improve early detection and monitoring of MS disease progression.
• UCSFcoreStrategic or Co-development PartnerClinical trial site partner for Roche MS Innovation Challenge research using Retitrack™ eye movement analysis as biomarker for MS progression.
• Sutter HealthcoreStrategic or Co-development PartnerClinical trial site partner for Roche MS Innovation Challenge research using Retitrack™ eye movement analysis as biomarker for MS progression.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C. Light Technologies